University of Florida Uses AI to Target Diabetes Care

Researchers are developing new treatments designed to minimize common drug side effects for juvenile and elderly patients.

Updated on Oct. 27, 2026 in Diabetes

University of Florida Uses AI to Target Diabetes Care

Live Poll

Do you support the use of artificial intelligence to accelerate the development of medical treatments?

University of Florida researchers are using artificial intelligence and supercomputing to identify new drug candidates for diabetes treatment. This initiative aims to address the limitations of existing therapies that often lead to adverse side effects for patients.

Why it matters

Many current diabetes medications are associated with complications like weight gain, pancreatic strain, and bone issues, often because they were developed without a full understanding of the disease's mechanisms. This research seeks to create more precise treatments by leveraging high-speed data processing.

The laboratory at the Herbert Wertheim UF Scripps Institute utilizes AI to analyze biological datasets, building on research methods first established by scientific director Patrick Griffin in 1991. The success of these predictive models for human outcomes remains under investigation.

The players

Patrick Griffin

Scientific director of the Herbert Wertheim UF Scripps Institute who has focused on metabolic and inflammatory disease research since 1991.

Herbert Wertheim UF Scripps Institute for Biomedical Innovation and Technology

A research entity at the University of Florida dedicated to investigating metabolic and inflammatory conditions.

The details

Researchers at the University of Florida are using supercomputing power to merge and decipher complex biological information that was previously difficult to map. By deploying AI programs, the team can analyze these datasets to predict which chemical compounds will effectively target the disease without the side effects common to current drugs. This computational approach allows for a deeper understanding of metabolic and inflammatory pathways.

1991: Patrick Griffin began his work on metabolic and inflammatory diseases.

Health Landscape

The shift toward AI-driven drug discovery at the Herbert Wertheim UF Scripps Institute marks a significant departure from traditional, trial-and-error pharmaceutical development. This approach reflects a growing effort to reduce treatment-related side effects in metabolic health.

While this research focuses on future drug development, it highlights the importance of monitoring for potential side effects with your current diabetes medications. If you have concerns about weight changes or other issues with your treatment, discuss them with your physician.

The takeaway

Artificial intelligence is changing how researchers approach drug discovery for metabolic diseases by predicting compound safety before human trials. Patients should continue to work closely with their medical team to manage symptoms and discuss any concerns regarding current treatment plans.